Brokerages Set Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) PT at $40.50

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) have been given a consensus rating of “Moderate Buy” by the nine ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $40.50.

Several research analysts have issued reports on the company. JPMorgan Chase & Co. raised their target price on Olema Pharmaceuticals from $29.00 to $32.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. Oppenheimer boosted their target price on shares of Olema Pharmaceuticals from $45.00 to $48.00 and gave the company an “outperform” rating in a research report on Thursday, December 11th. Guggenheim initiated coverage on shares of Olema Pharmaceuticals in a research report on Wednesday, October 8th. They issued a “buy” rating and a $20.00 price target on the stock. Zacks Research upgraded shares of Olema Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 9th. Finally, UBS Group reissued a “buy” rating on shares of Olema Pharmaceuticals in a research report on Monday, October 20th.

Olema Pharmaceuticals Price Performance

Shares of OLMA opened at $27.34 on Thursday. The firm has a fifty day simple moving average of $18.92 and a two-hundred day simple moving average of $10.68. The firm has a market cap of $1.88 billion, a PE ratio of -14.62 and a beta of 1.87. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.01. Olema Pharmaceuticals has a 1-year low of $2.86 and a 1-year high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.05). On average, equities analysts anticipate that Olema Pharmaceuticals will post -2.33 EPS for the current year.

Key Headlines Impacting Olema Pharmaceuticals

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Seeking Alpha reiterates a “Strong Buy” on Olema driven by initiation of the OPERA‑02 pivotal trial and promising combo data (palazestrant + KISQALI), highlighting OPERA‑01 readout in 2H‑2026 and OPERA‑02 topline in 2028 as key value catalysts. Seeking Alpha – Strong Buy on OPERA‑02
• Positive Sentiment: Several sell‑side firms have raised targets and reiterated buys (Goldman, Citi, JPMorgan, UBS), lifting the consensus price target (~$40.50 average), which supports upside if clinical milestones land.
• Neutral Sentiment: Reported short interest data shows effectively zero shares short and a 0.0 days‑to‑cover figure, indicating short sellers are not currently positioned to amplify moves (data appears to show no measurable short interest for December).
• Negative Sentiment: Director Ian T. Clark sold 264,800 shares on Dec. 19 at ~$29.73 (≈$7.87M), a large director‑level disposal that can raise governance/lockup concern and pressure the stock. SEC Form 4 – Clark sale 12/19/2025
• Negative Sentiment: Naseem Zojwalla executed multiple large sales (100,000; 70,000; 99,509 shares across Dec. 19–23), reducing his stake materially and generating roughly $7.5M+ in proceeds across those trades. SEC Form 4 – Zojwalla sales
• Negative Sentiment: David C. Myles sold 51,000 shares on Dec. 19 at ~$30.46 (~$1.55M), trimming his holding by ~8.5%—another insider sale contributing to near‑term selling pressure. SEC Form 4 – Myles sale 12/19/2025

Insiders Place Their Bets

In other news, insider David C. Myles sold 51,000 shares of the firm’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $30.46, for a total value of $1,553,460.00. Following the transaction, the insider owned 551,881 shares of the company’s stock, valued at $16,810,295.26. This trade represents a 8.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ian T. Clark sold 264,800 shares of Olema Pharmaceuticals stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $29.73, for a total value of $7,872,504.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 585,309 shares of company stock worth $16,956,383 over the last quarter. 16.36% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Olema Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. purchased a new stake in shares of Olema Pharmaceuticals in the third quarter worth $53,000. Ameritas Investment Partners Inc. lifted its stake in shares of Olema Pharmaceuticals by 55.4% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company’s stock valued at $26,000 after buying an additional 2,168 shares in the last quarter. Farther Finance Advisors LLC boosted its holdings in Olema Pharmaceuticals by 602.9% in the 2nd quarter. Farther Finance Advisors LLC now owns 6,839 shares of the company’s stock worth $29,000 after buying an additional 5,866 shares during the period. FNY Investment Advisers LLC increased its stake in Olema Pharmaceuticals by 100.0% in the 2nd quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company’s stock worth $42,000 after buying an additional 5,000 shares in the last quarter. Finally, Quarry LP purchased a new stake in Olema Pharmaceuticals in the 1st quarter worth $45,000. 91.78% of the stock is currently owned by institutional investors.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.